KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Finished Goods (2018 - 2025)

Ionis Pharmaceuticals has reported Finished Goods over the past 8 years, most recently at $2.1 million for Q1 2025.

  • Quarterly results put Finished Goods at $2.1 million for Q1 2025, up 959.0% from a year ago — trailing twelve months through Mar 2025 was $2.1 million (up 959.0% YoY), and the annual figure for FY2024 was $276000.0, up 79.22%.
  • Finished Goods for Q1 2025 was $2.1 million at Ionis Pharmaceuticals, up from $276000.0 in the prior quarter.
  • Over the last five years, Finished Goods for IONS hit a ceiling of $2.1 million in Q1 2025 and a floor of $63000.0 in Q3 2024.
  • Median Finished Goods over the past 5 years was $288000.0 (2022), compared with a mean of $563294.1.
  • Biggest five-year swings in Finished Goods: plummeted 87.02% in 2021 and later soared 959.0% in 2025.
  • Ionis Pharmaceuticals' Finished Goods stood at $390000.0 in 2021, then crashed by 57.95% to $164000.0 in 2022, then fell by 6.1% to $154000.0 in 2023, then soared by 79.22% to $276000.0 in 2024, then soared by 667.39% to $2.1 million in 2025.
  • The last three reported values for Finished Goods were $2.1 million (Q1 2025), $276000.0 (Q4 2024), and $63000.0 (Q3 2024) per Business Quant data.